SRRK

Scholar Rock is a biotech company developing apitegromab, a therapeutic candidate that has received a Complete Response Letter from the FDA and requires resolution of manufacturing deficiencies before potential approval. The company is focused on bringing apitegromab to market, which has received orphan drug and fast track designations, and is at the stage of addressing regulatory feedback to advance toward commercialization. Scholar Rock will need to establish manufacturing capabilities and commercial infrastructure to launch the drug if regulatory approval is ultimately obtained.

Pipeline

Catalyst Calendar